Effects Of Besifloxacin Drug! Trivia Facts Quiz

10 Questions | Total Attempts: 33

SettingsSettingsSettings
Please wait...
Effects Of Besifloxacin Drug! Trivia Facts Quiz

.


Questions and Answers
  • 1. 
    The besifloxacin molecule has been modified from what basic molecular structure to increase potency against and minimize the resistance of bacterial targets?1-3 The clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10-10 for Staphylococcus aureus and <7 x 10-10 for Streptococcus pneumonia
    • A. 

      Quinolone

    • B. 

      Aminoglycoside

    • C. 

      Macrolide

  • 2. 
    The addition of an N1 cyclopropyl moiety to the basic quinolone structure increased lethality by what mechanism?4 The clinical significance of these in vitro data has not been established.
    • A. 

      It binds to cleaved DNA only

    • B. 

      It binds to DNA gyrase only

    • C. 

      It binds to the enzyme-DNA pocket

  • 3. 
    Which 2 halogens contribute to the potency and broad-spectrum efficacy of besifloxacin®?3,5 The clinical significance of these in vitro data has not been established.
    • A. 

      Chlorine and bromine

    • B. 

      Bromine and fluorine

    • C. 

      Chlorine and fluorine

  • 4. 
    By what factor of the inhibition of DNA gyrase increased when a fluorine molecule is added to the C6 position of the basic quinolone structure?1 The clinical significance of these in vitro data has not been established.
    • A. 

      2X

    • B. 

      5X

    • C. 

      10X

  • 5. 
    Besifloxacin contains a C6 fluorine molecule, which improves activity against which bacterial type?1 The clinical significance of these in vitro data has not been established.
    • A. 

      Gram-positive bacteria

    • B. 

      Gram-negative bacteria

    • C. 

      Both gram-negative and gram-positive bacteria

  • 6. 
    Early addition of a bulky piperazine ring to the C7 position of the basic quinolone structure improved activity against which organisms?1 The clinical significance of these in vitro data has not been established.
    • A. 

      Gram-positive bacteria

    • B. 

      Gram-negative bacteria

    • C. 

      Anaerobic bacteria

  • 7. 
    To which position was a chlorine molecule added to make BESIVANCE® a chlorofluoroquinolone with increased potency?3 Clinical significance of these in vitro data has not been established.
    • A. 

      C8

    • B. 

      C9

    • C. 

      C10

  • 8. 
    BESIVANCE® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of which bacterial species?6 BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarus* *Efficacy for this organism was studied in fewer than 10 infections.  
    • A. 

      Aerococcus viridans, Pseudomonas aeruginosa, and Moraxella catarrhaslis

    • B. 

      Staphylococcus aureus and Staphylococcus epidermidis

    • C. 

      Both choices A and B, among others. Please see prescribing information for complete indication.

  • 9. 
    The dually halogenated structure of BESIVANCE® confers potent and balanced inhibition of which 2 bacterial enzymes?6,9,10 Clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10-10 for Staphylococcus aureus and <7 x 10-10 for Streptococcus pneumoniae
    • A. 

      DNA polymerase I and DNA ligase

    • B. 

      Helicase and primase

    • C. 

      DNA gyrase and topoisomerase IV

  • 10. 
    At minimum, how many mutations must a bacterium accumulate to develop significant levels of resistance to BESIVANCE®?11 Clinical significance of these in vitro data has not been established. In vitro studies demonstrated cross-resistance between BESIVANCE® and some fluoroquinolones. In vitro resistance to BESIVANCE develops via multiple-step mutations and occurs at a general frequency of <3.3x 10-10 for Staphylococcus aureus and <7 x 10-10 for Streptococcus pneumoniae.
    • A. 

      1

    • B. 

      2

    • C. 

      3